Table 3 Associations between LncRNA MALAT1 rs3200401 genotypes and survival of advanced NSCLC patients
Genotypes | Patients (%) | Deaths | MST (months) | Log-rank P | Crude HR (95% CI) | Crude P | Adjusted HR (95% CI)a | Adjusted P |
|---|---|---|---|---|---|---|---|---|
All patients | ||||||||
 CC | 259 (66.4) | 219 | 15.9 | --- | 1.00 (Reference) | --- | 1.00 (Reference) | --- |
 CT | 120 (30.8) | 94 | 22.6 | 0.045 | 0.78 (0.61–0.99) | 0.046 | 0.82 (0.64–1.05) | 0.119 |
 TT | 11 (2.8) | 8 | 21.8 | 0.353 | 0.71 (0.35–1.44) | 0.345 | 0.73 (0.36–1.50) | 0.392 |
 CT + TT | 131 (33.6) | 102 | 21.8 | 0.034 | 0.78 (0.61–0.98) | 0.034 | 0.81 (0.64–1.04) | 0.094 |
Adenocarcinoma | ||||||||
 CC | 119 (68.4) | 99 | 19.3 | --- | 1.00 (Reference) | --- | 1.00 (Reference) | --- |
 CT | 48 (27.6) | 31 | 29.9 | 0.019 | 0.62 (0.41–0.93) | 0.020 | 0.65 (0.43–0.98) | 0.040 |
 TT | 7 (4.0) | 5 | 19.1 | 0.804 | 0.87 (0.36–2.15) | 0.767 | 0.89 (0.35–2.24) | 0.806 |
 CT + TT | 55 (31.6) | 36 | 28.9 | 0.024 | 0.65 (0.44–0.95) | 0.025 | 0.64 (0.44–0.95) | 0.025 |
Squamous cell carcinoma | ||||||||
 CC | 76 (63.3) | 62 | 17.9 | --- | 1.00 (Reference) | --- | 1.00 (Reference) | --- |
 CT | 42 (35.0) | 37 | 20.6 | 0.798 | 1.05 (0.70–1.59) | 0.800 | 1.14 (0.75–1.75) | 0.538 |
 TT | 2 (1.7) | 2 | 11 | 0.999 | 1.01 (0.25–4.13) | 0.992 | 1.46 (0.25–8.56) | 0.676 |
 CT + TT | 44 (36.7) | 39 | 20.6 | 0.805 | 1.05 (0.70–1.57) | 0.805 | 1.05 (0.70–1.57) | 0.805 |